Who can enter
- Children with relapsed or refractory (not responding to therapy) acute myeloid leukemia (R/R AML)
- Age: 12 years and older
The goal of this study is to research the safety and efficacy of the study drug SAR443579 in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
The drug that is being studied in this research, SAR443579, is an immunotherapy. SAR443579 is a molecule that is similar to an antibody. An antibody is a protein that is produced in the blood to combat diseases by attacking and destroying harmful cells and organisms such as bacteria and viruses.
SAR443579 is designed to bind the CD123 protein, produced by certain cancer cells, with one side of the molecule. The other side reacts with a protein that is produced by certain immune cells. Binding of a SAR443579 molecule to both cancer cell and immune cell may lead to activation of the immune cell, resulting in killing the cancer cells that produce CD123.
Research with laboratory animals with AML has shown that SAR443579 can have an effect on the progression of the disease.